Home / Going-concern warnings / Acumen Pharmaceuticals, Inc.
Filed 2026-03-26 路 Form 10-K 路 Accession 0001628280-26-021413 micro
Price before filing: $2.63 (2026-03-25 close, split/dividend-adjusted)
Market cap at flag: $161.2M (2026-03-26) 路 Latest: $122.1M (2026-10-16)
| Window | ABOS | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -4.2% | +8.9% | -13.1% | 2026-04-27 |
| 90 days | -12.2% | +11.9% | -24.1% | 2026-06-24 |
| 180 days | +0.8% | +18.3% | -17.6% | 2026-09-22 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 7 insiders sold $536K (44 sales)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-01-05 | Barton Russell Chief Operating Officer | Sale | 4,000 | $1.96 | $8K | no | Form 4 |
| 2026-01-05 | Meisner Derek M Chief Legal Officer & Corp Sec | Sale | 4,000 | $1.96 | $8K | no | Form 4 |
| 2026-01-05 | OConnell Daniel Joseph Chief Executive Officer, Director | Sale | 4,649 | $1.97 | $9K | no | Form 4 |
| 2026-01-05 | Siemers Eric Chief Medical Officer | Sale | 4,000 | $1.96 | $8K | no | Form 4 |
| 2026-01-05 | Zuga Matt CFO & Chief Business Officer | Sale | 4,000 | $1.96 | $8K | no | Form 4 |
| 2026-01-06 | Barton Russell Chief Operating Officer | Sale | 3,618 | $1.97 | $7K | no | Form 4 |
| 2026-01-06 | Meisner Derek M Chief Legal Officer & Corp Sec | Sale | 7,097 | $1.97 | $14K | no | Form 4 |
| 2026-01-06 | Meisner Derek M Chief Legal Officer & Corp Sec | Sale | 3,801 | $1.97 | $7K | no | Form 4 |
| 2026-01-06 | OConnell Daniel Joseph Chief Executive Officer, Director | Sale | 5,102 | $1.97 | $10K | no | Form 4 |
| 2026-01-06 | Siemers Eric Chief Medical Officer | Sale | 6,834 | $1.97 | $13K | no | Form 4 |
| 2026-01-06 | Zuga Matt CFO & Chief Business Officer | Sale | 5,100 | $1.97 | $10K | no | Form 4 |
| 2026-01-07 | Barton Russell Chief Operating Officer | Sale | 1,700 | $1.99 | $3K | no | Form 4 |
| 2026-01-07 | Doherty James J. President and CDO | Sale | 1,700 | $1.99 | $3K | no | Form 4 |
| 2026-01-07 | Meisner Derek M Chief Legal Officer & Corp Sec | Sale | 1,700 | $1.99 | $3K | no | Form 4 |
| 2026-01-07 | Meisner Derek M Chief Legal Officer & Corp Sec | Sale | 10,070 | $1.99 | $20K | no | Form 4 |
| 2026-01-07 | OConnell Daniel Joseph Chief Executive Officer, Director | Sale | 37,755 | $1.99 | $75K | no | Form 4 |
| 2026-01-07 | Schacterle Amy Chief Regulatory Officer | Sale | 1,097 | $1.98 | $2K | no | Form 4 |
| 2026-01-07 | Zuga Matt CFO & Chief Business Officer | Sale | 4,105 | $2.00 | $8K | no | Form 4 |
| 2026-01-07 | Zuga Matt CFO & Chief Business Officer | Sale | 1,700 | $1.99 | $3K | no | Form 4 |
| 2026-01-08 | Barton Russell Chief Operating Officer | Sale | 3,530 | $1.86 | $7K | no | Form 4 |
| 2026-01-08 | Doherty James J. President and CDO | Sale | 6,467 | $1.82 | $12K | no | Form 4 |
| 2026-01-08 | Meisner Derek M Chief Legal Officer & Corp Sec | Sale | 6,819 | $1.82 | $12K | no | Form 4 |
| 2026-01-08 | Meisner Derek M Chief Legal Officer & Corp Sec | Sale | 30,092 | $1.82 | $55K | no | Form 4 |
| 2026-01-08 | OConnell Daniel Joseph Chief Executive Officer, Director | Sale | 8,143 | $1.82 | $15K | no | Form 4 |
| 2026-01-08 | Zuga Matt CFO & Chief Business Officer | Sale | 6,888 | $1.82 | $13K | no | Form 4 |
| 2026-03-26: red flag filed | |||||||
Showing 25 of 44 transactions.
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-12-26 to 2026-04-25. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited financial statements included in this Annual Report on Form 10-K. The report from our independent registered public accounting firm for the year ended December 31, 2025 includes an explanatory paragraph stating that our recurring losses from..."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-K (period 2025-12-31)
Read the original filing on SEC.gov →
🔔 Get email alerts for this company
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.